WAG
IBRX icon

Wiser Advisor Group’s ImmunityBio IBRX Stock Holding History

Wiser Advisor Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23K Buy
3,000
+1,000
+50% +$6.85K 0.03% 122
2025
Q4 		$3.96K Hold
2,000
– – ﹤0.01% 203
2025
Q3 		$4.92K Buy
+2,000
New +$5.15K 0.01% 203
2025
Q2 		– Sell
-2,000
Closed -$6.02K – 137
2025
Q1 		$6.02K Buy
+2,000
New +$6.06K 0.01% 200

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Wiser Advisor Group's IBRX Position: Q1 2026 in Review

Wiser Advisor Group increased its ImmunityBio (IBRX) stake by 50% in Q1 2026, buying an estimated $6.85K and bringing the position to 3,000 shares worth $23K. The position accounts for 0.03% of the portfolio, ranked #122.

Wiser Advisor Group first reported a position in IBRX in Q1 2025 and has held it in 4 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Wiser Advisor Group held 3,000 shares of ImmunityBio worth $23K as of Q1 2026.
  • Wiser Advisor Group bought 1,000 ImmunityBio shares in Q1 2026, an estimated $6.85K.
  • ImmunityBio made up 0.03% of Wiser Advisor Group's portfolio in Q1 2026, its #122 holding.
  • Wiser Advisor Group first reported a position in ImmunityBio in Q1 2025 and has held it in 4 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Wiser Advisor Group's 13F filing for Q1 2026, filed 22 Apr 2026.